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Introduction: Tumor necrosis factor inhibitor (TNFi) therapy is effective for rheumatoid arthritis (RA). Some
researchers have suggested that TNFi therapy affects B-cell homeostasis. We studied the effect of TNFi therapy on
the distribution of peripheral B-cell subsets to elucidate B-cell–related biomarkers to predict the TNFi response.
Methods: Peripheral B cells were analyzed for expression of CD19, CD27, CD38 and immunoglobulin D in 31
healthy donors and 96 RA patients, including 21 patients who were followed 3 months after TNFi initiation.
Results: Treatment with steroids significantly altered the distribution of B-cell subsets. After we adjusted for age,
sex and steroid dose, we found that patients with RA had B-cell subset proportions similar to controls. B-cell subset
distributions did not differ upon use of TNFi at baseline or before or after TNFi introduction. TNFi responders
(according to European League Against Rheumatism criteria) at 3 months had significantly higher proportions of
CD27+ memory B cells at baseline, and ≥26% CD27+ cells at inclusion was associated with a relative risk of 4.9
(1.3 to 18.6) for response to TNFi treatment. CD27+ cells produced three times more TNFα than did TNFi-naïve B
cells and were correlated with interferon γ produced from CD4+ cells in patients without TNFi treatment.
Conclusions: In patients with RA, high levels of baseline memory B cells were associated with response to TNFi,
which may be related to TNFα-dependent activation of the T helper type 1 cell pathway.Introduction
Rheumatoid arthritis (RA) is a common autoimmune dis-
ease with a prevalence of 0.3% to 1% worldwide. The dis-
ease is often associated with reduced mobility, increased
social dependency and work-related disability [1]. RA is a
systemic inflammatory disease affecting the joint-lining
tissue, called the synovium. RA synovial tissue is cha-
racterized by increased numbers of macrophage-like and
fibroblast-like synoviocytes in the intimal lining layer and
infiltration of the sublining by macrophages, T and B cells,
and other inflammatory cells that promote inflammation
and destruction of bone and cartilage [2]. The intraarticular* Correspondence: c-daien@chu-montpellier.fr
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unless otherwise stated.and systemic expression of proinflammatory cytokines—
particularly tumor necrosis factor α (TNFα), interleukin 1
(IL-1) and IL-6, which are produced primarily by synovial
macrophages and synoviocytes—plays a crucial role in the
pathogenesis of RA, in that these cytokines can contribute
to the increased number of the fibroblast-like synoviocytes.
TNFα is one of the most potent proinflammatory cyto-
kines and is known to regulate cell survival, cell death
and/or cell growth, depending on the cell type [3]. The
blockage of TNFα with bioengineered compounds, ei-
ther antibodies or soluble receptor molecules, can ameli-
orate the symptoms and joint destruction due to RA
with remarkable efficacy. Two treatment strategies used
to neutralize TNFα include the monoclonal antibodies
infliximab and adalimumab; certolizumab pegol, a PEGy-
lated antigen-binding fragment of a humanized antibody;
and the soluble TNF receptor construct etanercept. The
fusion protein etanercept consists of the extracellulartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Fc portion of a human antibody. Of note, because TNF
receptors also bind the TNF ligand lymphotoxin α, eta-
nercept antagonizes TNFα as well as lymphotoxin α.
TNF antagonists modulate disease development mainly
by their anti-inflammatory properties. The multiple bio-
logical responses include reducing the production of
proinflammatory cytokines, chemokines and acute-phase
proteins; decreasing the expression of adhesion molecules;
attenuating vascular permeability and angiogenesis; deacti-
vating epithelial, endothelial and dendritic cells, as well as
myofibroblasts and osteoclasts; increasing the number of
circulating regulatory T cells; and diminishing the recruit-
ment of inflammatory cells from blood to the inflamed tis-
sue. Recently, TNF antagonists were suggested to regulate
B-cell homeostasis [4,5].
B cells play a prominent role in RA because they pro-
duce rheumatoid factor (RF) and anticitrullinated peptide
antibodies (ACPAs), which are well-established indicators
of disease and disease severity and precede the onset of
disease by many years. The pathogenic roles of these auto-
antibodies in RA was strongly suggested by the amplifi-
cation of tissue injury by ACPAs in collagen-induced
arthritis [6]. Moreover, B cells have antibody-independent
functions that include cytokine secretion, antigen presen-
tation and organization of other inflammatory cells. B cells
play a crucial role in the development of tertiary lymphoid
tissue within the inflamed synovium that seems to amplify
autoimmune responses. B cells of the germinal center–like
structures in the synovium are essential for CD4 T-cell ac-
tivation. Depletion of B cells inhibits the T-cell production
of interferon γ (IFN-γ), which is involved in the immune
response, and of IL-1 in the rheumatoid synovium [7].
However, data concerning circulating B-cell subsets in
RA are controversial [4,8,9]. Two studies focused on the
possible effects of TNF inhibitor (TNFi) therapy on B
cells, exploring whether such inhibition could help in
the efficacy of B cells [4,5]. One study showed an in-
crease in the proportion of preswitch memory B cells
after TNFi therapy, and the other showed a decreased
proportion of memory B cells in patients receiving TNFi
therapy. The reasons for the differing findings are un-
clear, but they may be related to the cohort composition.
An interesting difference between the two studies is the
TNF antagonist used. Souto-Carneiro et al. used the
anti-TNF monoclonal antibody infliximab [4], whereas
Anolik and coworkers used the soluble TNF receptor fu-
sion protein etanercept [5].
In our present study, we analyzed the effect of 3-
month treatment with versus without TNFi therapy on
the distribution of memory B cells in patients with active
RA who were receiving synthetic disease-modifying anti-
rheumatic drugs (DMARDs). We also compared the use
of monoclonal antibody and soluble receptor TNFitherapy. We assessed baseline B-cell phenotypes associ-
ated with TNFi response and analyzed B-cell subset
composition in a large cohort of RA patients and con-




We enrolled consecutive patients with RA who met the
2010 American College of Rheumatology/European League
Against Rheumatism (ACR/EULAR) criteria for RA [10].
Use of prednisone was permitted if doses were <10 mg/day
and stable for at least 1 week, with the same requirement
for synthetic DMARDs if doses were stable for at least
3 months. Patients who had previously received rituximab
were excluded. All of these patients were included in the
transversal study comparing RA patients with controls and
patients naïve to TNFi treatment with those currently on
TNFi therapy (regardless of the number of TNFi agents
previously taken). Some patients were followed after the
initiation of TNFi treatment. These patients were also re-
cruited consecutively. A TNFi was introduced because of
the presence of active disease (Disease Activity Score in 28
joints (DAS28) >3.2) despite treatment with synthetic
DMARDs. For this longitudinal study, the inclusion criteria
were, as for the transversal study, 2010 ACR/EULAR cri-
teria fulfillment, prednisone doses <10 mg/day and stable
for at least 1 week, and synthetic DMARDs and stable for
at least 3 months. Moreover, these patients had to be naïve
to any biological treatment. Controls were chosen on the
basis of being in the same age range as the RA patients.
They were either blood donors or patients seen in rheuma-
tology departments for osteoarthritis, vertebral discopathy
or other mechanical pain and free of any general pathology
or infection.
Clinical and biological data were collected at baseline
and at 3 months after TNFi therapy introduced at base-
line. The DAS28 scores and concomitant treatments
were evaluated at each time point. Response to treat-
ment was defined on the basis of EULAR criteria [11]: a
decrease in DAS28 score >0.6 between baseline and
3 months, with a DAS28 score <5.1 at 3 months. All pa-
tients gave their written informed consent to participate
in the study, which was approved by the Medical Ethics
Committee of Nimes University Hospital, France (2012-
A00592-41).
Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from blood collected in ethylenediaminetetraacetic
acid tubes by using of Ficoll reagent (Ficoll-Paque Plus;
STEMCELL Technologies, Vancouver, BC, Canada). After
gating lymphocytes using side scatter area/forward scatter
(FSC) area and excluding doublets using FSC height/FSC
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Canto II cell analyzer; BD Biosciences, San Jose, CA, USA)
with the antibodies BD Horizon V450-conjugated anti-
CD19 (BD Biosciences), phycoerythrin (PE) anti–immuno-
globulin D (anti-IgD) (BD Pharmingen, San Diego, CA,
USA), PE/cyanine 7 (PE/Cy7) anti-CD38 (BD Pharmingen),
and allophycocyanin anti-CD27 (BD Pharmingen). A mini-
mum of 100,000 events in the lymphocyte gate were ac-
quired. Memory B cells were defined as CD19+CD27+
lymphocytes with preswitch and postswitch memory B cells
(CD27+IgD+ and CD27+IgD−) and double-negative memory
B cells as CD27−IgD−. Naïve B cells were defined as
CD19+CD27−IgD+ lymphocytes. The results are expressed
as the percentage of positive cells. All analyses involved
the use of fresh blood. We secondarily calculated the abso-
lute number of cells using the routine complete blood
count values when available.
Cells from some patients were frozen in fetal calf serum
(FCS) with 10% dimethyl sulfoxide and kept at −80°C.
Unfrozen cells were used to assess TNFα production from
B-cell subsets and IFN-γ from CD4+ cells. For TNFα as-
sessment, PBMCs were cultured in RPMI 1640 medium
with 10% FCS for 4 hours with phorbol 12-myristate 13-
acetate (0.1 μg/ml), ionomycin (0.5 μg/ml) and brefeldin A
(10 μg/ml) (PIB). For CD4+ IFNg+ determination, PBMCs
were cultured for 24 hours with anti-CD3 and anti-CD28
antibodies with PIB for the last 4 hours [12]. Activated
cells were stained with anti-CD19, anti-CD27 and anti-
IgD antibodies or with anti-CD19, anti-CD27 and anti-
CD4 antibodies. Next, cells were permeabilized with
BD Cytofix/Cytoperm buffer solution (BD Biosciences)
and stained with PE–anti-TNF or PE/Cy7–anti-IFN-γ
antibodies.
Statistical analysis
Patient characteristics are described with percentages for
categorical variables and mean ± SD or median (interquar-
tile range) values for continuous variables. The distribu-
tion of continuous variables was tested by performing the
Shapiro-Wilk test. Multivariate linear regression analysis
was used to compare B-cell subset proportions adjusted
for age, sex and steroid dose. The correlation of B-cell sub-
sets and continuous variables was assessed by Spearman
correlation. The variation in B-cell subset distribution
between baseline and 3 months was assessed by per-
forming a paired Student’s t-test or Wilcoxon signed-rank
test. Comparison of B-cell distribution by TNFi type at
3 months involved a linear mixed model. This model in-
cluded a subject-specific random intercept and fixed ef-
fects of time and groups (with and without adjustment for
age, sex and steroid dose). Comparison of B-cell subset
distributions between EULAR-defined responders and
nonresponders was carried out using Student’s t-test or
the Mann–Whitney U test. We determined a cutoffbaseline level of B cells associated with EULAR response
using receiver operating characteristic curve analysis and
maximizing the Youden index (sensitivity + specificity − 1).
We anticipated that we would need a minimum sample
size of eight patients to detect an increase of 3.5 ± 1.5% in
CD27+ population between baseline and 3 months, as pre-
viously reported by Souto-Carneiro et al. [4], with a power
of 90% and an α value of 0.05 (considering a null intraindi-
vidual correlation). Statistical analyses were carried out
using SAS version 9.3 software (SAS Institute, Cary, NC,
USA). Two-tailed P-values <0.05 were considered statisti-
cally significant.Results
Patients
To assess B-cell distribution in RA, we included 96 pa-
tients with RA and 31 controls (71% and 68% females, re-
spectively, with mean age ± SD = 59 ± 13 years and 51 ±
16 years, respectively). For assessment of the TNFi effect,
we included 21 patients (75% female, median age = 57 years
(IQR == 50 to 62), median RA duration 7 years (IQR = 2
to 28)). Eleven patients received etanercept and ten were
given monoclonal antibodies (one was given adalimumab
and nine received certolizumab pegol) (Table 1).Effect of glucocorticoid treatment on B-cell composition
Sex significantly influenced the composition of CD27+IgD−
postswitch memory, CD27−IgD+ naïve and CD27−IgD− B
cells in controls (with, respectively, 10.9 (5.9 to 13.5), 76.7
(73.1 to 83.4) and 2.2 (1.7 to 2.5) in men and 20.9 (12.4 to
27.9), 65.7 (49.9 to 76.4) and 4.4 (2.8 to 7.4) in women; all
P < 0.05), but not in RA patients. In controls, age was posi-
tively correlated with the proportion of CD27−IgD− B cells
(r = 0.42, P = 0.02), whereas age in RA patients was in-
versely correlated with only CD27+IgD+ preswitch memory
B cells (r = −0.19, P = 0.04). Administration of steroids af-
fected the distribution of B-cell subsets. Steroid dose was
positively correlated with the proportion of memory B cells
(r = 0.25, P = 0.008) and inversely with that of naïve B cells
(r = −0.23, P = 0.02) (Table 2). Steroid users had greater
proportions of memory B cells, especially postswitch mem-
ory B cells, and lesser proportions of naïve B cells than
nonusers (P = 0.01, P 0.02 and P 0.006, respectively). These
results strongly support the need to take into account ster-
oid treatment when comparing controls and RA patients.
After adjustment for age, sex and steroid dose, B-cell com-
position did not differ between RA patients and controls
(Table 3), between controls and never-treated patients with
RA, or between controls and patients with active RA
(DAS28 score ≥3.2). In terms of absolute values, there
was a global B-cell lymphopenia in RA patients (Additional
file 1).
Table 1 Patient and control characteristics at baselinea










(N = 31) (N = 96) (N = 18) (N = 58) (N = 21) (N = 21)
Monoclonal antibodies/soluble receptors (n) – – – – 12/9 10/11
Females (%) 68 71 78 71 76 75
Age, yr (mean ± SD) 51 ± 16 59 ± 13 59 ± 16 58 ± 14 59 ± 11 59 ± 11
RA duration, yr (median (IQR)) – 10 (4 to 21) 4 (3 to 19) 8 (3 to 22) 9 (5 to 16) 7 (2 to 28)
RF positivity (%) – 76 76 68 80 81
ACPA positivity (%) – 76 76 71 74 71
RF- and ACPA-negative (%) 21 22 21 19 19
Radiographic erosions (%) – 73 65 67 81 71
Ongoing synthetic DMARD (%) – 69 0 46 71 77
Previous TNFi (%) – 36 0 0 86 0
Previous use of other biologic drugs (n) – 40 0 0 19 0
Use of steroids (<10 mg/day) (%) 0 60.4 50.0 53.3 66.6 54.5
Current steroid dose (mg/day) 0 5 (0 to 9) 2.5 (0 to 7.8) 2.5 (0 to 7.6) 5.5 (0 to 8.6) 5 (0 to 9.2)
C-reactive protein level (mg/dl) – 1.1 (0.4 to 2.4) 0.8 (0.3 to 2.8) 0.9 (0.4 to 1.9) 1.9 (0.8 to 2.8) 1.4 (0.4 to 2.6)
DAS28 score (median (IQR)) – 4.2 (3.4 to 5.5) 4.2 (3.4 to 5.0) 3.9 (3.3 to 4.7) 5.7 (5.1 to 6.4) 4.5 (2.8 to 5.0)
aACPA, Anticitrullinated peptide antibody; DAS28, Disease Activity Score in 28 joints; DMARD, Disease-modifying antirheumatic drug; RA, Rheumatoid arthritis;
RF, Rheumatoid factor; TNFi, Tumor necrosis factor inhibitor. DMARD-naïve patients and patients at baseline of TNFi introduction are included in the TNFi-naïve
patient group. TNFi ongoing patients are different from all the other subgroups. All analyses are adjusted for age, sex and glucocorticoid dose.
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treatment on B-cell subset distribution
RA duration was inversely correlated with proportion of B
cells (CD19+) among lymphocytes (r = −0.23, P = 0.02),
but not B-cell subset distribution. The number of previous
TNFi agents used was inversely correlated with proportion
of CD27−IgD− B cells (r = −0.21; P = 0.03 and P = 0.01 after
adjustment for steroid dose) (Table 2). After adjustment
for age, sex and steroid dose, as compared with patients
with low disease activity (DAS28 score <3.2), patients with
active disease showed greater proportions of CD27−IgD−
B cells (5.6 ± 3.9 vs 4.9 ± 2.6; P = 0.008) and memory B
cells (27.7 ± 14.4 vs. 19.5 ± 10.7; P = 0.05), especially pre-
switch memory B cells (10.2 ± 7.5 vs. 5.3 ± 3.3; P = 0.04).
No difference was found in the distribution of B-cell sub-
sets between patients with versus without RF after adjust-
ment for age, sex and steroid dose.Table 2 Correlation of rheumatoid arthritis characteristics an
Lymphocytes (%) B cells (%)
Characteristics CD19+ CD27+ C
RA duration, yr −0.23b −0.11 −
Steroid dose, mg/day −0.06 0.25c 0.
TNFi agents used (n) −0.16 −0.15 −
DAS28 score 0.03 0.10c 0.
aDAS28, Disease Activity Score in 28 joints; Ig, Immunoglobulin; RA, Rheumatoid art
were not significant; however CD27+, CD27+IgD+ and CD27−IgD− proportions were
adjustment for age, sex and steroid dose (general linear models). Data are SpearmaEffect of tumor necrosis factor inhibitor therapy on B-cell
distribution
After adjustment for age, sex and steroid dose, TNFi-naïve
patients (n = 58) and those receiving TNFi therapy at base-
line (n = 21) did not differ in B-cell subset distribution.
Among patients receiving TNFi therapy at baseline, nine
received etanercept and twelve were given monoclonal
antibodies. Patients who received etanercept and mono-
clonal antibodies did not differ in B-cell subset distribu-
tion, nor did TNFi-naïve patients or patients receiving the
two TNFi types. The number of B cells significantly in-
creased 3 months after TNFi initiation, from a median of
5.3% (IQR 3.9 to 6.3) to 7.7% (6.7 to 10.6) (P < 0.01), with
no change in B-cell subset distribution (Table 3). The
change in median proportions of CD27−IgD− B cells dif-
fered with etanercept and monoclonal antibody treat-
ment (+1.6% (0.0 to 5.4) vs. 0.3% (−1.3 to 1.8) of B cells;d B-cell subset distributionsa
D27+IgD+ CD27+IgD− CD27−IgD+ CD27−IgD−
0.10 −0.13 0.07 0.08
20 0.27c −0.23b 0.16
0.07 −0.17 0.16 −0.21b
18c 0.02 −0.10 −0.04c
hritis; TNFi, Tumor necrosis factor inhibitor. bP < 0.05, cP < 0.01. cCorrelations
higher in patients with active RA than in those with low disease activity after
n’s r statistics.
Table 3 Distribution of B-cell subsets in patients and controlsa




TNFi ongoing p3 Baseline TNFi introduction p4
Baseline 3 months
CD19+ 6.8 (2.5 to 8.7) 4.4 (3.3 to 6.1) 4.1 (3.1 to 9.6) NS NS 4.8 (3.6 to 7.4) 4.4 (3.1 to 6.3) NS 5.3 (3.9 to 6.3) 7.7 (6.7 to 10.6) **
(% lymphocytes)
CD27+ 22.0 (18.7 to 34.8) 25.4 (16.8 to 37.6) 34.4 (17.6 to 44.4) NS NS 25.2 (17.7 to 36.4) 30.0 (11.7 to 42.7) NS 28.3 (19.6 to 36.2) 28.4 (19.0 to 39.6) NS
(% CD19+)
CD27+IgD+ 10.4 (6.2 to 15.5) 8.0 (4.6 to 13.2) 8.0 (4.3 to 10.0) NS NS 8.0 (4.9 to 12.9) 10.5 (4.1 to 15.2) NS 9.3 (5.4 to 14.2) 7.5 (3.4 to 12.7) NS
(% CD19+)
CD27+IgD− 15.4 (10.2 to 21.7) 16.6 (11.0 to 25.3) 22.2 (13.8 to 39.1) NS NS 15.2 (10.7 to 24.4) 17.3 (9.2 to 28.6) NS 15.9 (12.7 to 24.5) 21.3 (13.2 to 24.8) NS
(% CD19+)
CD27−IgD+ 73.1 (58.2 to 77.1) 65.7 (54.2 to 77.1) 58.5 (45.4 to 74.8) NS NS 68.5 (56.8 to 77.0) 65.0 (50.9 to 82.1) NS 63.5 (54.4 to 76.7) 62.1 (49.6 to 73.7) NS
(% CD19+)
CD27−IgD− 2.8 (1.9 to 4.5) 4.7 (3.0 to 7.2) 5.8 (3.2 to 9.5) NS NS 4.7 (3.0 to 6.7) 3.8 (2.9 to 7.5) NS 4.7 (3.0 to 6.9) 6.8 (4.2 to 10.3) NS
(% CD19+)
aDMARD, Disease-modifying antirheumatic drug; Ig, Immunoglobulin; NS, Not significant; p1, P-value comparing controls and all RA patients; p2, P-value comparing controls and DMARD-naïve patients; p3, P-value
comparing TNFi-naïve and TNFi ongoing (currently taking TNFi agent); p4, P-value comparing baseline and 3-month data for patients with TNFi introduced at baseline; RA, Rheumatoid arthritis; TNFi, Tumor necrosis
factor inhibitor. CD27+ memory B cells, CD27+IgD+ preswitch memory B cells, CD27+IgD− postswitch memory B cells, CD27−IgD+ naïve B cells, CD27−IgD− double-negative B cells, CD38high plasmablasts. All values are
















Figure 1 Proportion of CD27+ memory B cells predicts response to tumor necrosis factor inhibitor therapy. (A) Patients with response
(R) or no response (NR) (according to European League Against Rheumatism (EULAR) criteria) to tumor necrosis factor inhibitor (TNFi) at baseline
(M0) (P = 0.01). The gray line indicates 26% of memory B cells, the best threshold at which to separate responders and nonresponders. (B) Levels
of CD27+ B cells at baseline correlated with change in Disease Activity Score in 28 joints (DeltaDAS28) during the first 3 months of TNFi
treatment (P = 0.05). Each data point represents one participant. Horizontal bars are medians, and whiskers are IQR (25th to 75th percentile).
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however, this finding was no longer significant (P =
0.09). In terms of absolute values, there was no signifi-
cant change between TNFi-naïve and TNFi-ongoing pa-
tients nor between baseline and 3 months after TNFi
introduction (Additional file 1).
Baseline B-cell phenotypes as predictors of tumor
necrosis factor inhibitor response
We compared baseline proportions of B-cell subsets
among EULAR criteria–defined responders and nonre-
sponders at 3 months. Baseline B-cell subset proportion
was correlated with DAS28 score in the first 3 months of
treatment, with significant differences for CD27+ memory
B cells (Figure 1). CD27+ B-cell proportion at baseline was
greater for EULAR criteria–defined responders than non-
responders at 3 months (30.8% (27.2 to 39.1) vs. 19.6%
(13.6 to 26.1) of CD19+ cells; P = 0.01) (Figure 1). Baseline
CD27+ B-cell proportion was inversely correlated withFigure 2 Threshold of 26% for CD27+ B cells as a predictor of tumor
proportion ≥26% and <26% at baseline and Disease Activity Score in 28 jo
therapy (P = 0.01). (B) Association of CD27+ B-cell proportion ≥26% at base
18.6); P = 0.02). Each data point represents one participant. Horizontal barsDAS28 score at 3 months (r = −0.40, P = 0.05). Notably,
CD27+ memory B-cell proportion at baseline was not cor-
related with DAS28 score at the time of inclusion and was
similar for patients with and those without RF. Responders
and nonresponders had received similar doses of prednis-
one at baseline.
Determination of predictive baseline threshold of CD27+
B cells
To further explore the use of CD27+ B-cell proportion
for prognosis, we defined a threshold proportion of 26%
(sensitivity = 92%, specificity = 71%, Youden index = 63%,
positive predictive value = 85% and negative predictive
value = 83%). For patients with ≥26% CD27+ B cells at
baseline, DAS28 score was lower at 3 months (P < 0.05)
and the relative risk of response was 4.9 (95% confidence
interval = 1.3 to 18.6) (Figure 2). Of note, patients with
CD27+ B cells ≥26% or <26% had received similar doses
of steroids at baseline.necrosis factor inhibitor response. (A) Association of CD27+ B-cell
ints (DAS28) after 3 months of tumor necrosis factor inhibitor (TNFi)
line and European League Against Rheumatism response (4.9 (1.3 to
are medians, and whiskers are IQR (25th to 75th percentile).
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cytometry
We next analyzed the mechanisms underlying the predict-
ive value of CD27+ B cells and assessed intracellular TNFα
levels by flow cytometry. TNFα production was greater by
threefold from CD27+ B cells than naïve B cells (18.8%
(11.3 to 41.7) vs. 5.9% (2.3 to 14.7) of positive CD19+ cells;
P < 0.001) (Figure 3A). Production of TNFα was greater
from CD27+ memory B cells than from treatment-naïve B
cells, and CD27+ memory B cells were inversely correlated
with IFN-γ-producing CD4+ cells in TNFi-naïve patients.
The results of previous work have suggested that B cells
can activate IFN-γ production in CD4+ T cells via TNFα.
We therefore correlated the proportion of CD4+IFN-γ+
cells in patients with and without TNFi (n = 8 vs. n = 14)
with that of CD27+ memory B-cell levels. In patients not
receiving TNFi, the proportion of CD27+ B cells was po-
sitively correlated with that of CD4+IFN-γ+ cells (r = 0.58,
P < 0.05), but not in patients receiving TNFi (r = 0.01, P =
0.94) (Figure 3B).
Discussion
In the present study, we found B-cell lymphopenia in RA
patients, with a similar distribution of naïve and memoryFigure 3 CD27+ memory B cells were greater producers of tumor nec
interferon γ–producing CD4+ cells in tumor necrosis factor–naïve pat
by CD27+ memory B cells and naïve CD27−IgD+ B cells in 14 rheumatoid a
one participant. Horizontal bars are medians, and whiskers are IQR (25th to
(B) Correlation of proportion of CD27+ memory B cells and interferon γ (IFN
and with therapy (TNFi+, n = 8).B cells between RA patients and controls. Proportions of
CD27−IgD−, CD27+ and CD27+IgD+ memory B cells were
higher in patients with active than in those with low-level
disease. TNFi therapy globally increased CD19+ B-cell pro-
portions without modifying B-cell subset proportions. Of
note, a high proportion of CD27+ memory B cells at base-
line was associated with good clinical response to TNFi.
Although B cells are considered to have an important
role in RA, data concerning B-cell subsets in the periph-
eral blood of patients with RA remain controversial.
Souto-Carneiro et al. described a decreased proportion of
CD27+IgD+ preswitch memory B cells in patients with RA
and an increased proportion of CD27+IgD− postswitch
memory B cells in patients with long-term RA versus
short-term RA and controls [4]. Anolik et al. did not find
any change in the proportion of B-cell subsets in patients
with RA [8]. de la Torre et al. found an increased propor-
tion of only double-negative B cells [13]. Tony et al. found
an increased proportion of CD27+ cells in RA patients
positive for RF versus RA patients negative for RF and
controls [9]. In a large cohort of 208 patients with RA,
Sellam et al. found a decreased proportion of CD19+ total
B cells and CD27+IgD− B cells in RA patients, but no dif-
ferences in proportions of global memory B cells or naïverosis factor α than naïve B cells and inversely correlated with
ients. (A) Flow cytometry of tumor necrosis factor α (TNFα) production
rthritis (RA) patients at baseline (P < 0.001). Each data point represents
75 percentile). IgD, Immunoglobulin D; SSC-A, Side-scatter area
-γ)–producing CD4+ cells in patients without therapy (TNFi−, n = 14)
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CD27 staining is generally accepted, but other markers
could be used. Indeed, CD27+IgD− postswitch memory B
cells are mainly IgG+ or IgA+, but they can also contain a
small fraction of IgM-only memory cells. Memory B cells
can also be assessed using a Bm1 to Bm5 classification,
with memory B cells being CD38+IgD− and CD38−IgD−
(early and late Bm5, respectively). We might have missed
differences between the studied groups because of the lack
of Bm1 to Bm5 and IgM, IgG and IgA assessment.
We found that age and sex as well as steroid dose were
important confounding factors that must be taken into
account when comparing RA patients and controls, even
at low steroid doses (<10 mg/day). Adjusted analyses
eliminated biases, which could explain the contradictory
results of other studies. After adjusting our analyses on
these three variables, we found no differences in the pro-
portions of all B-cell subsets between controls and all
RA patients or never-treated RA patients. Proportions
of CD27−IgD−, CD27+ and CD27+IgD+ memory B cells
were greater in patients with active rather than low dis-
ease activity. These subsets are all memory B cells, as
suggested by previous work on double-negative B cells
[15,16]. Memory B cells accumulate in the synovium
[17]. Because analysis of B cells in the peripheral blood
is affected by B cells in the joint compartment, the in-
creased production of memory B cells in the peripheral
blood of RA patients may be compensated by joint mi-
gration. With active disease, however, the increase in the
proportion of memory B cells could concern both per-
ipheral blood and the joint compartment.
Data concerning the effect of TNFi therapy on B cells
are also controversial. In a cross-sectional study, Anolik
et al. found decreased proportions of circulating total
CD27+ memory B cells in patients with RA receiving eta-
nercept (n = 34) compared with patients receiving metho-
trexate (n = 17) and healthy controls [5]. Sellam et al. found
an increased proportion of CD19+ and a decreased propor-
tion of CD27−IgD− B cells in patients receiving methotrex-
ate and TNFi (n = 142) compared with patients receiving
methotrexate alone (n = 66) [14]. These results were not ad-
justed for age, sex or steroid dose. In longitudinal studies,
Souto-Carneiro et al. found an increased proportion of
CD27+IgD+ B cells after infliximab treatment in 15 pa-
tients with RA [4], whereas Roll et al. found an increased
proportion of CD27+ B cells after TNFi in RF-negative RA
patients, but not in RF-positive RA patients [9].
In the present study, analyses adjusted for age, sex and
steroid dose revealed a similar B-cell distribution in pa-
tients receiving TNFi and TNFi-naïve patients. We con-
firmed the increase in total CD19+ proportion found by
Sellam et al. [9], but we did not find any significant
changes in proportions of B-cell subset distributions
after the introduction of TNFi. We could not assess theinfluence of RF positivity on changes in B-cell subset
proportions, because our sample included only four RF-
negative patients receiving TNFi. The data did not differ
between use of monoclonal antibodies and the soluble
receptor etanercept. Therefore, TNFi seems to globally
increase the proportion of all B-cell subsets with respect
to their normal distribution in peripheral blood.
As mentioned previously, TNFi therapy does not mod-
ify the proportion of B-cell subsets in peripheral blood.
To explain the predictive value of memory B cells, their
function should be altered by TNFi. In fact, we show
that memory B cells could produce three times more
TNFα than could naïve B cells. B cells are an important
source of TNFα, as shown by other previous studies, as
well as being the main producer of lymphotoxin α
[18,19]. This finding could explain why baseline memory
B cell levels affected the TNFi response. However, other
sources of TNFα are more abundant, such as macro-
phages. Menard et al. reported that IFN-γ expression in
splenic host T cells in B-cell–deficient mice was greater
with B-cell transfer from infected than naïve mice (19).
This IFN-γ production was mediated by the TNFα and
cellular contact between B and CD4+ cells, as shown by
the lack of efficacy of TNFα−/−B-cell transfer and by cul-
turing CD4+ T and B cells separately in transwell plates
[20]. Indeed, B cells amplified IFN-γ production by T
cells via a TNFα-mediated mechanism. To further explore
this hypothesis, we examined the relationship between
memory B cells and CD4+IFN-γ+ T helper type 1 (Th1)
cells. The proportion of CD27+ B cells and CD4+IFN-γ+
Th1 cells was correlated in patients free of TNFi, but not
in patients currently taking TNFi. This indirect argument
might suggest the importance of TNFα produced by B
cells to induce the Th1 pathway in a microenvironment.
Studies aimed at better exploring the relation between
memory B cells produced in the TNFα and Th1 pathways
are required.
The results of our present study are particularly inter-
esting in the context of studies of patients receiving ri-
tuximab therapy. Other research groups have found a
high proportion of baseline CD27+ memory B cells asso-
ciated with poor clinical response and early relapse with
rituximab therapy [14,21], whereas we found an associ-
ation of TNFi therapy with good clinical response. Not-
ably, in the work by Sellam et al. [9], the mean baseline
CD27+ proportion was 26.8% for rituximab responders
and 35.9% for nonresponders. CD27+ <26% at baseline
may be a valuable threshold to distinguish TNFi nonre-
sponders who may respond better to rituximab therapy.
However, this threshold needs to be confirmed in other
cohorts receiving TNFi and rituximab. Moreover, further
studies are needed to address whether CD27+ memory
B-cell levels can predict response to a second or a third
TNFi therapy.
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The distribution of B-cell subsets in blood is influenced
by age, sex and glucocorticoid dose, but it does not dif-
fer between patients with RA and controls. Patients
with active RA have an increased proportion of memory
B cells. Among the B-cell subsets, memory B cells are
the most important TNFα producers, and this produc-
tion is correlated with Th1 activation. Use of a TNFi ap-
pears to inhibit TNFα-mediated interaction between B
and CD4+ cells, thus leading to decreased IFN-γ pro-
duction by CD4+ T cells. High baseline levels of CD27+
memory B cells was found to be associated with a
EULAR-criteria defined response to TNFi therapy, along
with a 4.9-fold increased chance of response among
patients with CD27+ levels ≥26%. Although further val-
idation is needed, these findings might become an im-
portant tool in clinical practice.
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